Influence of body mass index on serum PSA concentration for prostate cancer screening.

LÓPEZ LAUR JD; PÉREZ ELIZALDE R; DI MILTA N; RECALDE GM; VANRELL MC; MASELLI ME; LÓPEZ FONTANA CM

Santiago de Chile

Congreso; SIU World Uro-oncology Update Santiago 2008; 2008

SIU

(POSTER) INFLUENCE OF BODY MASS INDEX ON SERUM PSA CONCENTRATION FOR PROSTATE CANCER SCREENING López Laur JD, Pérez Elizalde R, Di Milta N, Recalde GM, Vanrell MC, Maselli ME, López Fontana CM Introduction: Recent studies have suggested that obesity may play a role in prostate cancer (CaP) development and progression. It has been associated to a more aggressive and advanced tumor at the moment of diagnosis. The aim of this study was to determine the influence of Body Mass Index (BMI) on serum prostate-specific antigen (PSA) concentration for CaP screening. METHODS: A sample of 74 men from 50 to 80 years old was selected for the study. They were free of CaP, had not undergone prostate surgery or taken medications known to alter androgen levels. The study consisted of a body composition measurement by weight, height and BMI; and a blood test including hemogram and serum PSA determination. The statistical analysis was carried out by ANOVA and Pearson coefficient (p=0.05). RESULTS: The mean age was 57.3 years old and the mean BMI of 28.3 kg/m2. Subjects with BMI between 20-25 kg/m2 (n=13) showed a mean serum PSA concentration of 2.16 ng/ml, while those with BMI between 25-30 kg/m2 (n=43) had a mean serum PSA of 1.85 ng/ml and those with BMI > 30kg/m2 (n=18) had a mean serum PSA of 0.92 ng/ml. The serum PSA concentration was significantly lower in obese volunteers showing an inverse correlation between BMI and serum PSA (r= -0.27; p=0.001). CONCLUSION: These findings suggest that obese men have lower serum PSA concentrations than non obese men being a possible cause of late diagnostic of CaP in this group of people.